IFM Investors Pty Ltd grew its stake in shares of McKesson Co. (NYSE:MCK) by 7.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,629 shares of the company’s stock after buying an additional 900 shares during the period. IFM Investors Pty Ltd’s holdings in McKesson were worth $1,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC raised its position in shares of McKesson by 161.2% during the fourth quarter. Proficio Capital Partners LLC now owns 222 shares of the company’s stock valued at $25,000 after buying an additional 137 shares during the last quarter. Bedel Financial Consulting Inc. raised its position in shares of McKesson by 165.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 236 shares of the company’s stock valued at $26,000 after buying an additional 147 shares during the last quarter. Dubuque Bank & Trust Co. raised its position in shares of McKesson by 106.7% during the first quarter. Dubuque Bank & Trust Co. now owns 341 shares of the company’s stock valued at $40,000 after buying an additional 176 shares during the last quarter. Old North State Trust LLC raised its position in shares of McKesson by 53.3% during the fourth quarter. Old North State Trust LLC now owns 391 shares of the company’s stock valued at $43,000 after buying an additional 136 shares during the last quarter. Finally, IMS Capital Management bought a new stake in shares of McKesson during the third quarter valued at approximately $57,000. Hedge funds and other institutional investors own 86.60% of the company’s stock.
Shares of MCK opened at $114.10 on Friday. McKesson Co. has a fifty-two week low of $106.11 and a fifty-two week high of $160.84. The firm has a market capitalization of $21.89 billion, a P/E ratio of 8.52, a price-to-earnings-growth ratio of 1.15 and a beta of 1.24. The company has a current ratio of 1.02, a quick ratio of 0.57 and a debt-to-equity ratio of 0.81.
The company also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Shareholders of record on Friday, March 1st were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 1.37%. The ex-dividend date was Thursday, February 28th. McKesson’s payout ratio is 12.36%.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of McKesson from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Wolfe Research started coverage on shares of McKesson in a research report on Tuesday, April 2nd. They issued an “outperform” rating on the stock. ValuEngine cut shares of McKesson from a “sell” rating to a “strong sell” rating in a research report on Friday, March 1st. Barclays restated a “hold” rating and issued a $130.00 price target on shares of McKesson in a research report on Friday, February 1st. Finally, Deutsche Bank upgraded shares of McKesson from a “sell” rating to a “hold” rating and set a $175.00 price target on the stock in a research report on Friday, January 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. McKesson currently has a consensus rating of “Hold” and an average target price of $134.90.
TRADEMARK VIOLATION WARNING: This story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://dakotafinancialnews.com/2019/04/21/mckesson-co-mck-stake-raised-by-ifm-investors-pty-ltd.html.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
See Also: Cost of Equity
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.